{
    "company_name": "NEUROTECH INTERNATIONAL LIMITED",
    "address": "Suite 5 CPC, 145 Stirling Hwy, NEDLANDS, WA, AUSTRALIA, 6009",
    "summary": "Development of wearable neurotechnology devices to assist with neurological\nconditions such as autism.",
    "details": "Development of wearable neurotechnology devices to assist with neurological\nconditions such as autism.",
    "website": "http://www.neurotechinternational.com/",
    "stock_code": "NTI",
    "links": "['#genesis-nav-primary', '#genesis-content', '#genesis-footer-widgets', 'https://neurotechinternational.com/', 'https://neurotechinternational.com/', '', 'https://neurotechinternational.com/board-and-management/', 'https://neurotechinternational.com/corporate-directory/', 'https://neurotechinternational.com/corporate-governance/', 'https://neurotechinternational.com/corporate-videos/', '#', 'https://neurotechinternational.com/biopharmaceutical-trials/', 'https://neurotechinternational.com/biopharmaceutical-trials/#combination-therapy', 'https://neurotechinternational.com/biopharmaceutical-trials/#pathways-to-commercialisation', 'https://www.mentetech.com/', '', 'https://neurotechinternational.com/investor-dashboard/', 'https://neurotechinternational.com/asx-announcements/', 'https://neurotechinternational.com/investor-conference-calls/', 'https://neurotechinternational.com/company-reports/', 'https://neurotechinternational.com/presentations/', 'https://neurotechinternational.com/research/', 'https://neurotechinternational.com/./news-and-media/', 'https://neurotechinternational.com/fact-sheets/', 'https://neurotechinternational.com/right-to-receive-documents/', 'https://neurotechinternational.com/contact/', '#home-content', 'https://neurotechinternational.com/biopharmaceutical-trials/', 'https://neurotechinternational.com/wp-content/uploads/Bioshares-Positive-Phase-II-Study-Results-for-Neurotech-International-in-Autism.pdf', 'https://neurotechinternational.com/asx-announcements/', 'https://youtu.be/wdM5Flwea0w', 'https://juststocks.com.au/neurotech-international-extends-rett-syndrome-study-with-novel-cannabinoid-drug/', 'https://stockhead.com.au/health/neurotech-extends-clinical-trials-for-the-us2bn-rett-syndrome-market/#new_tab', 'https://smallcaps.com.au/neurotech-international-extends-nti164-rett-syndrome-trial-52-weeks/#new_tab', 'https://neurotechinternational.com/news-and-media/', 'mailto:info@neurotechinternational.com', 'https://whitenoisecomms.com']",
    "images": "https://neurotechinternational.com/wp-content/uploads/neurotech-international-logo-inverse.svg, https://neurotechinternational.com/wp-content/uploads/grass-bg.jpg, https://neurotechinternational.com/wp-content/uploads/mother-and-son.jpg, https://neurotechinternational.com/wp-content/uploads/neurotech-international-logo-inverse.svg",
    "company_logo_link": "https://neurotechinternational.com/wp-content/uploads/neurotech-international-logo-inverse.svg"
}